A diabetes drug brand needed to improve new-to-brand (NBRx) conversions amid high campaign costs across 50+ publishers. IQVIA linked audience quality, publisher performance, and prescription data to evaluate ROI. Seven key publishers were identified as effective endemic/lifestyle partners across diabetes, migraine, and oncology. By shifting to a portfolio approach, the client negotiated analytics subsidies, cutting costs by $1M while expanding reach. Insights enabled better investment decisions, stronger leverage with media partners, and more efficient omnichannel campaigns.

Join for free to read